JP7181881B2 - プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 - Google Patents

プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 Download PDF

Info

Publication number
JP7181881B2
JP7181881B2 JP2019542356A JP2019542356A JP7181881B2 JP 7181881 B2 JP7181881 B2 JP 7181881B2 JP 2019542356 A JP2019542356 A JP 2019542356A JP 2019542356 A JP2019542356 A JP 2019542356A JP 7181881 B2 JP7181881 B2 JP 7181881B2
Authority
JP
Japan
Prior art keywords
days
subject
pharmaceutical composition
rnai agent
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019542356A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531357A5 (https=
JP2019531357A (ja
Inventor
ペーテル・ワインガールト
デイヴィッド・カレンド
Original Assignee
ザ メディシンズ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60388127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7181881(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ザ メディシンズ カンパニー filed Critical ザ メディシンズ カンパニー
Publication of JP2019531357A publication Critical patent/JP2019531357A/ja
Publication of JP2019531357A5 publication Critical patent/JP2019531357A5/ja
Priority to JP2022068684A priority Critical patent/JP7566815B2/ja
Application granted granted Critical
Publication of JP7181881B2 publication Critical patent/JP7181881B2/ja
Priority to JP2024173304A priority patent/JP7850215B2/ja
Priority to JP2025258789A priority patent/JP2026062719A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2019542356A 2016-10-18 2017-10-18 プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 Active JP7181881B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022068684A JP7566815B2 (ja) 2016-10-18 2022-04-19 プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法
JP2024173304A JP7850215B2 (ja) 2016-10-18 2024-10-02 プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法
JP2025258789A JP2026062719A (ja) 2016-10-18 2025-12-17 プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662409816P 2016-10-18 2016-10-18
US62/409,816 2016-10-18
US201662422028P 2016-11-14 2016-11-14
US62/422,028 2016-11-14
US201762472525P 2017-03-16 2017-03-16
US62/472,525 2017-03-16
US201762550426P 2017-08-25 2017-08-25
US62/550,426 2017-08-25
PCT/US2017/057218 WO2018075658A1 (en) 2016-10-18 2017-10-18 Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022068684A Division JP7566815B2 (ja) 2016-10-18 2022-04-19 プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法

Publications (3)

Publication Number Publication Date
JP2019531357A JP2019531357A (ja) 2019-10-31
JP2019531357A5 JP2019531357A5 (https=) 2021-10-21
JP7181881B2 true JP7181881B2 (ja) 2022-12-01

Family

ID=60388127

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019542356A Active JP7181881B2 (ja) 2016-10-18 2017-10-18 プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法
JP2022068684A Active JP7566815B2 (ja) 2016-10-18 2022-04-19 プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法
JP2024173304A Active JP7850215B2 (ja) 2016-10-18 2024-10-02 プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法
JP2025258789A Pending JP2026062719A (ja) 2016-10-18 2025-12-17 プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022068684A Active JP7566815B2 (ja) 2016-10-18 2022-04-19 プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法
JP2024173304A Active JP7850215B2 (ja) 2016-10-18 2024-10-02 プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法
JP2025258789A Pending JP2026062719A (ja) 2016-10-18 2025-12-17 プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法

Country Status (21)

Country Link
US (3) US20180104360A1 (https=)
EP (2) EP4397311A3 (https=)
JP (4) JP7181881B2 (https=)
KR (3) KR20250171391A (https=)
CN (4) CN110088283A (https=)
AU (2) AU2017346879B2 (https=)
CA (1) CA3042423A1 (https=)
CL (1) CL2019001047A1 (https=)
DK (1) DK3529360T3 (https=)
ES (1) ES2982911T3 (https=)
FI (1) FI3529360T3 (https=)
HR (1) HRP20240930T1 (https=)
HU (1) HUE067712T2 (https=)
IL (1) IL266066A (https=)
LT (1) LT3529360T (https=)
MX (2) MX2019004573A (https=)
PL (1) PL3529360T3 (https=)
PT (1) PT3529360T (https=)
RS (1) RS65725B1 (https=)
SI (1) SI3529360T1 (https=)
WO (1) WO2018075658A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL292159B1 (en) 2012-12-05 2026-04-01 Alnylam Pharmaceuticals Inc PCSK9 iRNA compositions and methods of using them
CN108348541A (zh) 2015-08-25 2018-07-31 阿尔尼拉姆医药品有限公司 用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物
EP4397311A3 (en) 2016-10-18 2024-10-16 Novartis AG Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
EP3719126B1 (en) 2017-12-01 2025-01-01 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
CA3083970A1 (en) 2017-12-01 2019-06-06 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
DK3719128T3 (da) 2017-12-01 2025-03-03 Suzhou Ribo Life Science Co Ltd Dobbelt-strenget oligonukleotid, sammensætning og konjugat bestaende dobbelt-strenget oligonukleotid, fremgangsmåde herfor og anvendelse heraf
EP3719127A4 (en) 2017-12-01 2021-10-20 Suzhou Ribo Life Science Co., Ltd. NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH IT, MANUFACTURING METHOD AND USE
CN110944675B9 (zh) 2017-12-01 2024-08-09 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
AU2018394875B2 (en) 2017-12-29 2023-08-03 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
WO2020038377A1 (zh) 2018-08-21 2020-02-27 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的药物组合物和缀合物及其用途
US11896674B2 (en) 2018-09-30 2024-02-13 Suzhou Ribo Life Science Co., Ltd. SiRNA conjugate, preparation method therefor and use thereof
WO2020135673A1 (zh) 2018-12-28 2020-07-02 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
MX2021008661A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso
KR20220011689A (ko) 2019-05-22 2022-01-28 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 핵산, 약제학적 조성물, 접합체, 제조 방법, 및 용도
US12590304B2 (en) 2019-05-22 2026-03-31 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
AU2020280439B2 (en) 2019-05-22 2025-08-14 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
CN113795582B (zh) 2019-05-24 2024-05-24 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
CN115066498A (zh) 2020-03-16 2022-09-16 阿尔戈诺特Rna有限公司 Pcsk9的拮抗剂
JP2025531341A (ja) * 2022-09-19 2025-09-19 カイロンノヴァ （シャーメン） バイオファーマ カンパニー，リミテッド 炭水化物－オリゴヌクレオチド複合体、薬物組成物および治療への応用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016506240A (ja) 2012-12-05 2016-03-03 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＰＣＳＫ９ｉＲＮＡ組成物及びその使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101484588B (zh) * 2006-05-11 2013-11-06 阿尔尼拉姆医药品有限公司 抑制pcsk9基因表达的组合物和方法
CN108348541A (zh) * 2015-08-25 2018-07-31 阿尔尼拉姆医药品有限公司 用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物
EP4397311A3 (en) 2016-10-18 2024-10-16 Novartis AG Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016506240A (ja) 2012-12-05 2016-03-03 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＰＣＳＫ９ｉＲＮＡ組成物及びその使用方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Circulation, 2014, Vol. 130, No. Suppl. 2, #11936
Drugs, 2021.2, Vol.81, No.3, pp.389-395
N. Engl. J. Med., 2017.1, Vol.376, No.1, pp.41-51
N. Engl. J. Med., 2017.4.13, Vol.376, No.15 , pp.1430-1440
心臓, 2013, Vol.45, No.6, pp.651-656

Also Published As

Publication number Publication date
JP2025016469A (ja) 2025-02-04
WO2018075658A1 (en) 2018-04-26
JP2026062719A (ja) 2026-04-10
HRP20240930T1 (hr) 2024-10-11
CN110088283A (zh) 2019-08-02
CN119700800A (zh) 2025-03-28
DK3529360T3 (da) 2024-07-15
JP7566815B2 (ja) 2024-10-15
SI3529360T1 (sl) 2024-08-30
AU2017346879B2 (en) 2023-11-30
HUE067712T2 (hu) 2024-11-28
CN119345221A (zh) 2025-01-24
US20260108631A1 (en) 2026-04-23
LT3529360T (lt) 2024-07-25
EP3529360A1 (en) 2019-08-28
AU2023263519A1 (en) 2023-12-07
EP4397311A2 (en) 2024-07-10
AU2017346879A1 (en) 2019-05-23
RS65725B1 (sr) 2024-08-30
KR20240067272A (ko) 2024-05-16
AU2023263519B2 (en) 2026-02-12
CN119318663A (zh) 2025-01-17
PL3529360T3 (pl) 2024-08-26
US20210093736A1 (en) 2021-04-01
MX2024004495A (es) 2024-05-08
ES2982911T3 (es) 2024-10-18
CL2019001047A1 (es) 2020-05-08
IL266066A (en) 2019-06-30
BR112019007843A2 (pt) 2019-10-01
KR20190077411A (ko) 2019-07-03
CA3042423A1 (en) 2018-04-26
MX2019004573A (es) 2019-10-07
KR20250171391A (ko) 2025-12-08
EP3529360B1 (en) 2024-04-17
JP2022109948A (ja) 2022-07-28
PT3529360T (pt) 2024-07-12
EP4397311A3 (en) 2024-10-16
US20180104360A1 (en) 2018-04-19
JP7850215B2 (ja) 2026-04-22
FI3529360T3 (fi) 2024-07-11
JP2019531357A (ja) 2019-10-31

Similar Documents

Publication Publication Date Title
JP7181881B2 (ja) プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法
O'Donoghue et al. Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN (a) reduction-DOSE finding study (OCEAN (a)-DOSE)
JP5964821B2 (ja) 痛風と高尿酸血症の処置
JP6568052B2 (ja) 心不全を治療するためのニューレグリンの徐放
JP2018203747A5 (https=)
AU2014229985B2 (en) Methods of treating colorectal cancer
JP2026021335A (ja) ａｐｏ（ａ）を標的化するコンジュゲートアンチセンス化合物を用いて心血管事象のリスクを低減する方法
KR20240040767A (ko) His 저감반응자의 치료
HK40113597A (en) Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction
WO2025059594A1 (en) METHODS FOR TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HeFH)
BR112019007843B1 (pt) Métodos para prevenção de eventos cardiovasculares através da redução de proteína pró-proteina convertase subtilisina/quexina tipo 9 (pcsk9)
EA040947B1 (ru) Способы профилактики явлений со стороны сердечно-сосудистой системы посредством снижения содержания белка пропротеиновой конвертазы субтилизин-кексинового типа 9 (pcsk9)
HK40013430B (en) Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction
HK40013430A (en) Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction
WO2026062050A1 (en) Obicetrapib for use in methods for treating a subject having heterozygous familial hypercholesterolemia (hefh) and/or atherosclerotic cardiovascular disease (ascvd)
TW202434264A (zh) 降低一級預防受試者中重大不良心血管事件風險之方法
KR20260042531A (ko) Pcsk9 억제제를 이용하여 콜레스테롤 관련 질환을 치료 또는 예방하기 위한 방법
NZ792465A (en) Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction
US20110262398A1 (en) Cardiac treatment using anti-fibrotic agents

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20200911

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20200914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210910

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211019

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220926

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221025

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221118

R150 Certificate of patent or registration of utility model

Ref document number: 7181881

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250